Genmab — Februar 2019
-
I guess you have to make the distinction between market and patent protection
-
the patent is valid from the point it is granted - and that has nothing to do with the indication. FDA can grant orphan drug status and give you market protection
-
I guess you have to hope for the latter if you are looking for protection
-
ok, clear. yes, i know Jan said that. At the same time i feel we never got a very good explanation of what really were the issues in those trials; it left me feeling that possibly with other combinations results could be different. But probably pure fiction pure fiction in my head...
-
JV on things that are dead. Especially dara in solids: https://www.youtube.com/watch?v=yR5Z4n1TdSI
-
E L on the other hand we only have preclinical work that says it might work ! Jan has promissed us data from the Carina study that never came and also data from solid study and we have never seen that either. When things goes wrong people are usually not that keen on presenting
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind